PE ratio relative to earnings growth — is the valuation justified?
—
PEG Ratio
—
Current Price
$86.03
TTM EPS
$4.63
P/E Ratio
18.58
Growth Rate
—
N/A
Sector
Healthcare
Drug Manufacturers - Specialty & Generic
Calculated
8/18/2026
3:04:22 PM
PEG Ratio Unavailable
EPS growth rate unavailable
Peer Comparison
Sample Size
2 peers
Industry Median PEG
0.77
25th Percentile
0.08
75th Percentile
1.46
Symbol
Company
PEG
P/E
Growth
vs ANIP
AMPH
Amphastar Pharmaceuticals, Inc.
0.08
11.6
146.0%
—
COLL
Collegium Pharmaceutical, Inc.
1.46
29.9
20.5%
—
How to Interpret PEG Ratio
PEG < 1.0 — Potentially Undervalued. The stock may be priced below its earnings growth rate, suggesting a potential buying opportunity.
PEG 1.0–2.0 — Fairly Valued. The stock price is roughly in line with its earnings growth. A PEG of 1.0 is often considered "fair value."
PEG > 2.0 — Potentially Overvalued. The stock may be priced above what its earnings growth justifies.
Limitations:PEG ratios are less reliable for financial firms (earnings driven by interest margins), companies with negative/zero earnings growth, and hypergrowth companies (>100% growth) where the ratio may appear misleadingly low. Always use PEG alongside other valuation metrics.
